More News and Clinical Research about Emerging Approaches in Schizophrenia

JCP
Anticholinergic Burden in Schizophrenia
Insights

October 31, 2024

In this video, Philip D. Harvey, PhD discusses anticholinergic burden in schizophrenia, highlighting its cognitive impact, particularly memory impairments linked to M1 receptor blockade. He underscores the heightened dementia…
Understanding Neurotransmitters in Schizophrenia Beyond Dopamine
news

October 30, 2024

Research has revealed that multiple neurotransmitters contribute to schizophrenia, suggesting the potential for non-dopaminergic therapies.
Cholinergic Neurotransmission’s Role in Schizophrenia Symptoms
news

October 28, 2024

Cholinergic neurotransmission, an overlooked target in schizophrenia, influences brain functions, offering an alternative to antipsychotics.
Managing Weight, Metabolic Syndrome, and Diabetes in Schizophrenia Patients
news

October 17, 2024

Managing weight gain, metabolic syndrome, and diabetes in schizophrenia patients demands attention to side effects and lifestyle factors.
The History of Dopaminergic Blockade in Schizophrenia
news

October 4, 2024

Schizophrenia remains a debilitating condition that’s prompted the development of both dopamine-based and emerging non-dopaminergic therapies.
Beyond Dopamine: Evaluating the Pipeline for Schizophrenia
news

October 4, 2024

New schizophrenia drugs targeting non-dopaminergic pathways show promise in overcoming the limitations of existing therapies.
Xanomeline-Trospium and Iclepertin Show Promise in Managing Cognitive Impairment in Schizophrenia
news

October 4, 2024

Schizophrenia can cause cognitive deficits, and though no effective treatments exist, trial drugs like KarXT and Iclepertin show promise.
Schizophrenia’s Acute Psychosis Crisis Calls for Novel Treatments
news

October 4, 2024

Side effects limit most schizophrenia treatments, but emerging drugs targeting alternative pathways show promise.
Xanomeline-Trospium Shows Promise in Schizophrenia with Fewer Side Effects
news

October 3, 2024

EMERGENT trials showed the newly approved xanomeline-trospium (Cobenfy) offers benefits and fewer side effects than older schizophrenia drugs.
Evaluating Pooled Data from the EMERGENT Study Programs
news

October 3, 2024

The 2024 SIRS Congress featured encouraging long-term data on KarXT, the first FDA-approved non-dopaminergic schizophrenia drug.
FDA Approves First New Schizophrenia Drug in Years
news

September 27, 2024

The FDA approved Cobenfy, the first schizophrenia drug in decades, offering a new treatment option.
JCP
Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia
Review Article

August 21, 2024

Patients with schizophrenia and cognitive impairment had a 100% increase in relapse-related hospitalizations and ER visits versus patients with no (or only mild) cognitive impairment.
, , , et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe